Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 14, Issue 1, 2009, Pages 59-67

  Hydock, David S ^a   Lien, Chia Ying ^a   Hayward, Reid ^a  

^a UNIVERSITY OF NORTHERN COLORADO   (United States)

Author keywords

Anthracycline; Cannabinoid; Echocardiography

Indexed keywords

ANANDAMIDE; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; EX VIVO STUDY; HEART FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; ARACHIDONIC ACIDS; BLOOD PRESSURE; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOXORUBICIN; ECHOCARDIOGRAPHY, DOPPLER; ENDOCANNABINOIDS; HEART DISEASES; HEART RATE; MALE; MYOCARDIAL CONTRACTION; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 61449164929     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248408329449     Document Type: Article

References (49)

1. Iarussi D., Indolfi P., Casale F., Martino V., Di Tullio MT, Calabro R. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs. 2005; 7: 67-76.
2. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23: 2629-2636.
3. Monti E., Prosperi E., Supino R., Bottiroli G. Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. Anticancer Res. 1995; 15: 193-197.
4. Nousiainen T., Jantunen E., Vanninen E., Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002; 86: 1697-1700.
5. Cole MP, Chaiswing L., Oberley TD, et al. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. Cardiovasc Res. 2006; 69: 186-197.
6. Spallarossa P., Garibaldi S., Altieri P., et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004; 37: 837-846.
7. DeAtley SM, Aksenov MY, Aksenova MV, et al. Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. Cancer Lett. 1999; 136: 41-46.
8. Yen HC, Oberley TD, Vichitbandha S., Ho YS, St Clair DK The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest. 1996; 98: 1253-1260.
9. Muraoka S., Miura T. Thiol oxidation induced by oxidative action of adriamycin. Free Radic Res. 2004; 38: 963-968.
10. Zucchi R., Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anticancer Agents. 2003; 3: 151-171.
11. Andreadou I., Sigala F., Iliodromitis EK, et al. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol. 2007; 42: 549-558.
12. Tesoriere L., Ciaccio M., Valenza M., et al. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J Pharmacol Exp Ther. 1994; 269: 430-436.
13. Hayward R., Hydock DS Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007; 46: 20-32.
14. Neilan TG, Doherty GA, Chen G., et al. Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin. Am J Physiol Heart Circ Physiol. 2006; 291: H532 - H536.
15. Chicco AJ, Hydock DS, Schneider CM, Hayward R. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol. 2006; 100: 519-527.
16. Chicco AJ, Schneider CM, Hayward R. Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol. 2005; 289: R424 - R431.
17. Chicco AJ, Schneider CM, Hayward R. Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol. 2006; 47: 182-189.
18. Ascensao A., Ferreira R., Oliveira PJ, Magalhaes J. Effects of endurance training and acute Doxorubicin treatment on rat heart mitochondrial alterations induced by in vitro anoxia-reoxygenation. Cardiovasc Toxicol. 2006; 6: 159-172.
19. Hasinoff BB Dexrazoxane use in the prevention of anthracycline extravasation injury. Future Oncol. 2006; 2: 15-20.
20. Cusack BJ, Gambliel H., Musser B., et al. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Chemother Pharmacol. 2006; 58: 517-526.
21. Agapito MT, Antolin Y., del Brio MT, Lopez-Burillo S., Pablos MI, Recio JM Protective effect of melatonin against adriamycin toxicity in the rat. J Pineal Res. 2001; 31: 23-30.
22. Berthiaume JM, Wallace KB Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007; 23: 15-25.
23. Breed JG, Zimmerman AN, Dormans JA, Pinedo HM Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. Cancer Res. 1980; 40: 2033-2038.
24. Wagner JA, Abesser M., Harvey- White J., Ertl G. 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J Cardiovasc Pharmacol. 2006; 47: 650-655.
25. Underdown NJ, Hiley CR, Ford WR Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol. 2005; 146: 809-816.
26. Wagner JA, Hu K., Karcher J., et al. CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol. 2003; 138: 1251-1258.
27. Bisogno T., Melck D., Bobrov M., et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J. 2000; 351: 817-824.
28. Bouchard JF, Lepicier P., Lamontagne D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci. 2003; 72: 1859-1870.
29. Sterin-Borda L., Del Zar CF, Borda E. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochem Pharmacol. 2005; 69: 1705-1713.
30. Di Filippo C., Rossi F., Rossi S., D'Amico M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol. 2004; 75: 453-459.
31. Lepicier P., Bouchard JF, Lagneux C., Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol. 2003; 139: 805-815.
32. Iliodromitis EK, Aggeli IK, Gaitanaki C., et al. p38-MAPK is involved in restoration of the lost protection of preconditioning by nicorandil in vivo. Eur J Pharmacol. 2008; 579: 289-297.
33. Ping P., Zhang J., Huang S., et al. PKC-dependent activation of p46/p54 JNKs during ischemic preconditioning in conscious rabbits. Am J Physiol. 1999; 277: H1771 - H1785.
34. House SL, Melhorn SJ, Newman G., Doetschman T., Schultz Jel J. The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2. Am J Physiol Heart Circ Physiol. 2007; 293: H354 - H365.
35. Arola OJ, Saraste A., Pulkki K., Kallajoki M., Parvinen M., Voipio-Pulkki LM Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000; 60: 1789-1792.
36. Jones SM, Kirby MS, Harding SE, et al. Adriamycin cardiomyopathy in the rabbit: alterations in contractile proteins and myocyte function. Cardiovasc Res. 1990; 24: 834-842.
37. Batkai S., Mukhopadhyay P., Harvey-White J., Kechrid R., Pacher P., Kunos G. Endocannabinoids acting at cb1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol. 2007; 293: H1689 - H1695.
38. Mukhopadhyay P., Batkai S., Rajesh M., et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007; 50: 528-536.
39. Batkai S., Osei-Hyiaman D., Pan H., et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/ reperfusion injury. FASEB J. 2007; 21: 1788-1800.
40. Belham M., Kruger A., Mepham S., Faganello G., Pritchard C. Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail. 2007; 9: 409-414.
41. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007; 49: 330-352.
42. Outomuro D., Grana DR, Azzato F., Milei J. Adriamycin-induced myocardial toxicity: new solutions for an old problem ? Int J Cardiol. 2007; 117: 6-15.
43. Kaiserova H., Simunek T., Sterba M., et al. New iron chelators in anthracycline-induced cardiotoxicity. Cardiovasc Toxicol. 2007; 7: 145-150.
44. Bjelogrlic SK, Radic J., Jovic V., Radulovic S. Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice. Basic Clin Pharmacol Toxicol. 2005; 97: 311-319.
45. Lebrecht D., Geist A., Ketelsen UP, Haberstroh J., Setzer B., Walker UA Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol. 2007; 151: 771-778.
46. Conklin KA Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther. 2005; 4: 110-130.
47. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist. 2003; 8 (suppl 2). 3-9.
48. Lorusso V., Manzione L., Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann Oncol. 2007; 18 (suppl 6). vi70 - vi73.
49. Hydock DS, Lien C. -Y, Schneider CM, Hayward R. Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. Med Sci Sports Exer. 2008; 40: 808-817.